Stay updated on Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedFooter revision label updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 in the page history.SummaryDifference0.1%

- Check49 days agoChange DetectedA new revision v3.4.2 was added to the history, replacing the previous v3.4.1.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 in the page history; no visible changes to study details or content.SummaryDifference0.1%

- Check78 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 from the page's revision history.SummaryDifference0.1%

- Check100 days agoChange DetectedRevision: v3.3.3 has been added to the history, and HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed from the page footer. These updates reflect minor metadata changes to the page's revision history.SummaryDifference0.1%

Stay in the know with updates to Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.